Innovative Glycan-based analysis for Cancer diagnostics
Sector: Hospital • Location: Slovakia
Source: EU Funding & Tenders Portal
Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for prelimi
- Status
- Closed
- Sector
- Hospital, Residential, Commercial
- Location
- Slovakia
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Innovative Glycan-based analysis for Cancer diagnostics
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening. If the combined results are suspicious, the patients undergo a biopsy to confirm PCa. Yet, there are 74% of needless biopsies representing a significant pain for PCa patients and societal/economic burden. Based on a great commercial outcome from the ERC grant (311532) granted to Dr. Jan Tkac (co-founder/CSO of Glycanostics), the company has developed an innovative, non-invasive, early PCa diagnostics using blood serum. Instead of quantifying PSA, the innovative PCa diagnostic assay detect glycan changes on PSA protein (it discriminates between “healthy” PSA and “sick” PSA and accurately quantify the clinically relevant “sick” PSA). The technology is covered by two EPO patent applications owned by the company. The PCa diagnostic test with 95% accuracy will be applied as a 2nd opinion test in case of suspicious results from PSA & DRE examinations prior sending to a biopsy. PCa DX kit will be launched for clinics/hospital & cancer centres (B2B) and Prostate check home test for user-friendly application at homes (B2C). Our PCa diagnostic technology is unique compared to our competitors focusing on analysis of other complex biomolecules such as a level of proteins, mRNA and circulating DNA. Moreover, we have competitive advantage over competitors in terms of cost per sample, assay accuracy, simplicity of the assay enabling the home testing and high-throughput. Glycanostics consists of 7 core team members, 4 business and 4 scientific advisors making a great and highly experienced team that will bring these innovative PCa early diagnostic products to the market. |
Location
Country | Slovakia |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Residential, Commercial |
Article published date | 2026-02-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Slovakia
- Modernisation of Cystic Fibrosis Centers in Košice and Ivano-Frankivsk
- Respect, Pride, Expertise
- Joint initiative to improve the quality of life of children with oncological diseases in the Transcarpathian, Košice and Prešov regions
- Facilitating access to health interventions on both sides of the border
- Improved access to the TEN-T network through upgrading roads in the areas of Podhale and Tvrdošín District
- Improving Health Care Services in Social Facilities
- Reducing Risks by Improving Interoperability between Slovakia and Hungary for Better Preparedness
- Cross-border Cooperation in Healthcare between the Hospitals of Balassagyarmat and Veľký Krtíš
